PSIL AdvisorShares Psychedelics ETF
Quote as of Aug 26, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 26.80 | Day Range | 26.29 – 27.02 |
| 52-Week Range | 15.63 – 27.02 | Volume | 23.17K |
| Avg Volume | 48.87K | AUM | $59.2M (Aug 27, 2026) |
| Expense Ratio | 1.84% | Yield (TTM) | 6.36% |
| NAV | 26.39 | Premium/Discount | -0.23% indicative |
| Inception | Sep 15, 2021 | Holdings | 25 |
| Issuer | AdvisorShares | Exchange | AMEX |
| Category | Healthcare | Index Tracked | Not stated in source data |
| CUSIP | 00768Y297 | ISIN | US00768Y2972 |
| Management | Actively managed (per issuer description) | ||
About this ETF
This actively managed Exchange Traded Fund (ETF) endeavors to meet its investment goals by typically allocating a minimum of 80% of its total net assets (including any capital secured through borrowing for investment purposes) into the securities of specific companies. To be eligible for inclusion, these companies must either derive at least half of their net revenue from, or commit 50% or more of their assets to, psychedelic compounds, their derivatives, or other financial instruments exhibiting similar economic characteristics. The fund's primary holdings consist of publicly traded life sciences firms focused on psychedelic medical treatments, in addition to other businesses involved in the broader psychedelics sector. It is important to note that this fund maintains a concentrated, non-diversified portfolio.
Description from the fund data provider · profile as of Aug 27, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +13.85% | +26.95% | +53.32% | +56.09% | +57.74% | +17.78% | — | — | -23.37% |
| Total return | +13.85% | +26.95% | +53.32% | +56.09% | +73.58% | +23.06% | — | — | -21.00% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Aug 25, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 1.84% | Annual cost of a $10,000 investment | $184.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Aug 22, 2026 — portfolio reporting date from the data provider; holdings are not live positions. 33 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | ATAIBECKLEY INC | ATAI | 11.96% | 935.36K | $6.9M |
| 2 | Definium Therapeutics, Inc | DFTX | 11.64% | 149.61K | $6.7M |
| 3 | COMPASS PATHWAYS PLC | CMPS | 10.50% | 454.54K | $6.1M |
| 4 | CYBIN INC | HELP | 8.02% | 367.43K | $4.6M |
| 5 | ALTO NEUROSCIENCE INC | ANRO | 5.06% | 85.15K | $2.9M |
| 6 | NRX PHARMACEUTICALS INC | NRXP | 5.03% | 816.02K | $2.9M |
| 7 | NEURONETICS INC | STIM | 4.49% | 864.50K | $2.6M |
| 8 | GH RESEARCH PLC | GHRS | 4.42% | 90.07K | $2.6M |
| 9 | BRIGHT MINDS BIOSCIENCES INC | DRUG | 4.26% | 31.77K | $2.5M |
| 10 | ABBVIE INC | ABBV | 4.22% | 9.20K | $2.4M |
| 11 | RELMADA THERAPEUTICS INC | RLMD | 4.22% | 525.48K | $2.4M |
| 12 | NEUROCRINE BIOSCIENCES INC | NBIX | 3.87% | 14.64K | $2.2M |
| 13 | JOHNSON & JOHNSON | JNJ | 3.73% | 7.97K | $2.2M |
| 14 | ALKERMES PLC | ALKS | 3.65% | 43.62K | $2.1M |
| 15 | SUPERNUS PHARMACEUTICALS INC | SUPN | 2.80% | 35.19K | $1.6M |
| 16 | NEUPHORIA THERAPEUTICS INC | NEUP | 2.07% | 302.79K | $1.2M |
| 17 | QUANTUM BIOPHARMA-B SUB VOT | QNTM | 1.95% | 327.78K | $1.1M |
| 18 | OPTIMI HEALTH CORP | OPTH | 1.80% | 207.91K | $1.0M |
| 19 | ELI LILLY & CO | LLY | 1.44% | 662 | $831.1K |
| 20 | PSYENCE BIOMEDICAL LTD | PBM | 1.32% | 175.69K | $760.7K |
| 21 | PASITHEA THERAPEUTICS CORP | KTTA | 1.05% | 1.12M | $605.5K |
| 22 | NUMINUS WELLNESS INC | NUMIF | 0.70% | 10.16M | $406.2K |
| 23 | INCANNEX HEALTHCARE INC | IXHL | 0.45% | 72.86K | $260.1K |
| 24 | IGC PHARMA INC | IGC | 0.43% | 812.35K | $250.2K |
| 25 | SILO PHARMA INC | SILO | 0.42% | 90.46K | $239.7K |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 6.36% | Paid (last 12 months) | $1.7039 |
| Frequency | Quarterly | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | Dec 22, 2025 | Last payment | $1.6839 (Dec 29, 2025) |
| Growth 1Y | +402.92% | Growth 3Y / 5Y (ann.) | — / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Dec 22, 2025 | Dec 22, 2025 | Dec 29, 2025 | $1.6839 |
| Sep 22, 2025 | Sep 22, 2025 | Sep 29, 2025 | $0.0201 |
| Jun 23, 2025 | Jun 23, 2025 | Jun 27, 2025 | $0.0119 |
| Mar 21, 2025 | Mar 21, 2025 | Mar 28, 2025 | $0.1634 |
| Dec 23, 2024 | Dec 23, 2024 | Dec 30, 2024 | $0.0548 |
| Sep 23, 2024 | Sep 23, 2024 | Sep 30, 2024 | $0.1087 |
| Sep 25, 2023 | Sep 26, 2023 | Sep 29, 2023 | $0.0336 |
| Sep 26, 2022 | Sep 27, 2022 | Sep 30, 2022 | $0.5421 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 40.17% / 71.42% | Sharpe 1Y / 3Y | 2.11 / 0.636 |
| Max drawdown 1Y / 3Y | -20.42% / -59.71% | Sortino 1Y | 3.27 |
| Beta vs S&P 500 (3Y) | 0.812 | Correlation vs S&P 500 (1Y) | 0.384 |
| Downside deviation 1Y | 25.93% | Risk-free rate used | 3.72% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Aug 26, 2026. Formulas →
Liquidity
| Volume today | 23.17K | Average volume | 48.87K |
| AUM | $59.2M | Premium/Discount | -0.23% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | $51.7K | +0.09% | $57.7M → $57.8M |
| 1 Week | $962.5K | +1.73% | $55.6M → $57.8M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for PSIL
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.